Explore the full record of transactions filed by REGIS ROCHE, Chairman of the Board. Insider active across 1 companies, notably Diagnostic Medical Systems. Aggregated, 3 filings have been recorded. Total volume traded: €9k. The latest transaction was filed on 22 May 2024 (Cession). Regulator: AMF. All data is openly available.
3 of 3 declarations
Régis Roche is a French executive recognized in the medical technology and industrial development ecosystem. His public profile is closely associated with Diagnostic Medical Systems (DMS) and its subsidiary DMS Imaging, a company focused on medical imaging systems. Available public disclosures indicate that he was appointed as a director of Diagnostic Medical Systems at the annual general meeting held on 18 July 2022, and then became Chairman of the Board of DMS Imaging on 12 September 2022. In June 2025, however, he stepped down from his role as a director within DMS Group, so this should be viewed as a recent, rather than current, position. His tenure at the group coincided with a broader governance transformation and strategic repositioning. Company communications stated that the new governance model was designed to support the group’s development, place shareholders back at the center of the strategy, and generate stronger capital-market momentum. Within that framework, Roche was involved during a period emphasizing organic growth, French-based industrial capacity, and the development of new higher-value imaging solutions. DMS’s own biographical materials describe Roche as holding a PhD in cellular and molecular biology from Aix-Marseille University, complemented by training in corporate strategy and finance at HEC Paris. This combination of scientific expertise and business training is particularly relevant in high-technology healthcare businesses, where innovation, regulation, manufacturing, and capital allocation must be managed together. The company also highlights his experience in governance, institutional relations, and network development. Beyond DMS, Roche appears to have held other mandates connected to innovation, industrial networks, and professional organizations, including an administrative role with the Eurobiomed competitiveness cluster. Overall, his profile reflects a governance-oriented executive with exposure to corporate structuring, growth strategy, and stakeholder engagement. In the DMS context, he represented a leadership style focused on industrial consolidation, product innovation, and the promotion of French medical-imaging expertise.